Line Program Health Swine H The production area is about 30,000 square metres. The production N capacity is 120,000 tons of Monoglycerides per year. SILO is the leader in the development and production of glycerides of short and medium chain fatty acids. th: SI LO Ag healt ain h 104 s Salmonella Clostridium p. Nutrition Program E.Coli t University of Parma - Professor Afro Quarantelli University of Florence - Professor M. Antongiovanni IRTA (Barcelona) Universidad Autonoma de Barcelona - Professor Rafael Codony Guelph University (Canada) - Professor Steve Leeson COMPANY WITH QUALITY SYSTEM CERTIFIED BY DNV since 1950 Via di S. Bartolo a Cintoia, 104 50142 Firenze - ITALY T +39 055 7332895 F +39 055 780676 Email info@silospa.com www.silospa.com 104 SILO patented 1-Monoglycerides from C1 to C7 for treating animals Patent n. EP 2 410 871 B1
SILOhealth 104 a special combination of 1-monglycerides to modulate microflora from mouth to caecum The synergistic combination of Short- and Medium Chain Monoglycerides ensures a strong and selective antibacterial action in stomach, small intestine, large intestine, caecum and liver. Organic acids and relevant salts like sodium or calcium butyrate have a very limited antibacterial efficacy at ph 6 or 7 (gut ph) since at ph 6 they are dissociated. SILOhealth 104 has a strong antibacterial efficacy even at ph 7against bacteria like Salmonella, E. coli, Clostridium p., but not against beneficial lactobacillus. In the table here below the Minimum Inhibitory Concentration of SILOhealth 104 is compared with that of organic acids and sodium butyrate. Public Animal Health Institute of Brescia and Forlì - L. Alborali, G. Tosi MIC on Salmonella spp, Clostridium p., E. coli spp, Lactobacillus acidophylus / Plantarum of SILOhealth 104 compared to organic acids & sodium butyrate ph Salmonella spp Clostridium p. E. coli spp Lactobacillus Acidophylus / Plantarum SILOhealth 104 4.5 0.06% 0.01% 0.12% No inhibition SILOhealth 104 7 0.06% 0.01% 0.12% No inhibition Formic Acid 6 1.5% 1.8% 1.6% == Propionic Acid 6 2.4% 2.6% 2.5% == Sodium Butyrate 6 2.8% 3% 2.9% == Caecum ph 6-7,5 Liver Stomach ph 1-4,5 Small intestine ph 6-7 SILOhealth 104 exerts a selection of anti-bacterial action from ph 4 to ph 7, that is from mouth to caecum
Trial in piglets to control diarrhea, Salmonella and E. coli Trial conducted by Public Animal Health Institute Bruno Ubertini - Dr. L. Alborali Treatments: Two groups of piglets with average starting weight of 7.7 kg were allocated into two experimental diets: the control group (665 piglets) received the basal diet without any supplement in drinking water; the treated group (678 piglets) was fed the same basal diet and a supplement of 1-Monoglycerides in drinking water (2 kg/ton of drinking water). Feed of both groups was supplemented with 3200 ppm of ZnO up-to 25 kg of live weight. The trial lasted for 52 days, up-to 30 kg of live weight. mortality reduced by 50%! 3.5 3 2.5 2 1.5 1 0.5 Mortality % 0 Control group 1-Monogycerides group 14 12 10 8 6 4 2 E. coli and Salmonella in intes nal tract Control group 1-Monogycerides group Reduction of E. coli and Salmonella in intestinal tract 0 E.coli Salmonella spp. Enrofloxacin / Cefquinome reduced by 90% 60 50 40 30 20 10 An obio cs injec ons 0 Control group 1-Monogycerides group
SILOhealth 104 NUTRITIONAL PROPERTIES blood vessels before SILOhealth 104 blood vessels after SILOhealth 104 SILOhealth 104 SILOhealth 104 directly stimulates the beneficial formation of new blood vessels in intestinal epithelium New blood vessels are able to transport more nutrients to intestinal epithelium and stimulate gut development and integrity +VILLI GROWTH The effects are: villi growth reparation of lesions in gut mucosa and tight junction dramatic increase of the intestinal surface for nutrients absorption energy delivery to colonocytes crypt depth increase in colon -GUT PERMEABILITY
SILOhealth 104 FIELD TRIAL IN NORTH ITALY TREATMENTS 104 L Control Group: 120 piglets Starting average weight 7.85 Dosages: 0.2% of microincapsulated Sodium Butyrate and 120 ppm of Colistine SILOhealth 104 group: 120 piglets Starting average weight 7.82 Dosages: 0.25% of SILOhealth 104L in the feed SILOhealth 104 Group Sodium Butyrate + Colis ne Number of piglets 120 120 Number of days 42 42 Average live weight at the beginning in kg 7.82 7.85 Average live weight at the end in kg 29.70 28.10 Weight gain in the period in kg 21.88 20.25 Weight gain /piglet / day in kg 0.520 0.482 Number of dead piglets 2 6 Total consumed feed / piglet in kg 33.49 33.39 Consumed feed / piglet / day in kg 0.797 0.795 FCR 1.53 1.65
SILOhealth 104 COMBINED EFFECTS angiogenetic effect on microvilli due to stimulation of new blood vessels formation inhibition of Clostridium p. pathogenicity through disruption of bacterial cell membrane - villi growth stimulation through angiogenetic action and consequent increased nutrients transport in blood mucosa lesions reparation by increasing microvascular endothelial cell motility (beneficial angiogenesis) and by micro-flora modulation tight junctions expression by increasing AMP-Activated Protein KINASE (AMPK) - activity on Occludin, Claudin-1, Claudin-4, ZO-1 inhibition of Salmonella pathogenicity - inhibition of E.coli pathogenicity Lactobacillus growth stimulation through down-regulation of - - pathogenicity island 1 gene - through down-regulation - of expression and inhibition of by down-regulating - pathogenicity island 1 gene Type III secretion system pathogenicity of harmful - expression and inhibition of bacteria - Type III secretion system (TTSS)
SILOhealth 104 PRODUCT CHARACTERISTICS AND USAGE SILOhealth 104 is a blend of short and medium chain fatty acids 1-Monoglycerides CHARACTERISTICS: USED TO: - Very stable up-to 230 C in ph range from 1 to 9 - Selective antibacterial action non-ph dependent - Odorless, non corrosive - Water-soluble - exert selective antibacterial action in entire digestive apparatus from mouth to the anus; - deliver prompt energy: due to short and medium chain fatty acids bonded with glycerol; - perform emulsifying effect, which enhances the digestion of other dietary lipids. Liquid SILOhealth 104 is used in dry feed (mash or pellets) or in liquid feed or in drinking water in all growing periods of piglets, growing pigs and sows. Energetic level: 11.000 Kcal / kg - Creep feed period: 1-2 kg / ton of feed - Nursery from 6 to 25-30 kg of live weight: 0.5-2.5 kg / ton of feed - Growing period 30-60 kg of live weight: 0.5-1 kg / ton of feed - Sows during last months of pregnancy: 1-2 kg / ton of feed - Powder SILOhealth 104 is used in dry feed (mash or pellets) in all growing periods of piglets, growing pigs and sows. Energetic level: 8.500 Kcal / kg - Creep feed period: 1-3 kg / ton of feed - Nursery from 6 to 25-30 kg of live weight: 0.5-4 kg / ton of feed - Growing period 30-60 kg of live weight: 0.5-1 kg / ton of feed - Sows during last months of pregnancy: 1-3 kg / ton of feed
Line Program Health Swine H The production area is about 30,000 square metres. The production N capacity is 120,000 tons of Monoglycerides per year. SILO is the leader in the development and production of glycerides of short and medium chain fatty acids. th: SI LO Ag healt ain h 104 s t University of Parma - Professor Afro Quarantelli University of Florence - Professor M. Antongiovanni Salmonella Clostridium p. Nutrition Program E.Coli IRTA (Barcelona) Universidad Autonoma de Barcelona - Professor Rafael Codony Guelph University (Canada) - Professor Steve Leeson COMPANY WITH QUALITY SYSTEM CERTIFIED BY DNV since 1950 Via di S. Bartolo a Cintoia, 104 50142 Firenze - ITALY T +39 055 7332895 F +39 055 780676 Email info@silospa.com www.silospa.com 104 SILO patented 1-Monoglycerides from C1 to C7 for treating animals Patent n. EP 2 410 871 B1